Conexiant
Login
  • The Analytical Scientist
  • The Cannabis Scientist
  • The Medicine Maker
  • The Ophthalmologist
  • The Pathologist
  • The Traditional Scientist
The Medicine Maker
  • Explore

    Explore

    • Latest
    • Features
    • Interviews
    • Business & Trends
    • Technology & Manufacturing
    • Product Profiles
    • White Papers

    Featured Topics

    • Biopharma
    • Small Molecules
    • Cell & Gene
    • Future of Pharma

    Issues

    • Latest Issue
    • Archive
    • Cell and Gene Therapy Supplement
  • Topics

    Topics

    • Drug Discovery
    • Development & Clinical
    • Formulation
    • Drug Delivery
    • Bioprocessing
    • Small Molecules
    • Cell and Gene
    • Facilities & Equipment
    • Outsourcing
    • Packaging
    • Supply Chain
    • Regulation & Standards
  • News & Blogs

    News & Blogs

    • Industry News
    • Research News
    • Blogs
  • Events
    • Live Events
    • Webinars
  • Community & Awards

    Community & Awards

    • Power List
    • Sitting Down With
    • Innovation Awards
    • Company of the Year Awards
    • Authors & Contributors
  • Multimedia
    • Video
    • Podcasts
    • eBooks
Subscribe
Subscribe
The Medicine Maker / Issues / 2015 / Articles / Jun / Amine Alchemy
Manufacture Small Molecules

Amine Alchemy

Transforming common chemicals into complex amines is the pharmaceutical equivalent of turning lead to gold

06/29/2015 1 min read

Share

Researchers from The Scripps Research Institute claim to have developed a new method for synthesizing amines, which they describe as being akin to “taking dirt, and then adding a bit of rust, putting it all in a blender and ending up with gold” (1). In fact, complex amines are often more expensive than gold because they can be challenging (or even impossible) to make using traditional methods. This includes many with particularly desirable properties for drug developers, such as resistance to breakdown by enzymes in the body.

“Amines are very polar and therefore difficult to purify and manipulate without protecting groups,” says Phil Baran, the Darlene Shiley Chair in Chemistry at the Scripps Research Institute, and leader of the study. “I think that one of the most exciting aspects with our method is that it might one day be used widely by industrial drug and agrochemical makers for the betterment of humanity. Many companies have already told me they are using the new method, including Bristol-Myers Squibb (BMS), who are actively using it in current medicinal chemistry programs.” BMS and Scripps have been working together for some time as part of a multilaboratory partnership. In one of their latest projects, scientists from Scripps and BMS found that mixing two abundant (and cheap) feedstock compounds – nitro(hetero)arenes and olefins – with an iron catalyst could generate a variety of complex amine-containing compounds, under very mild conditions. According to Baran, most scientists have nitroarenes and olefins on a shelf in their lab, but it is only when they are merged in a precise way that they are able to produce such a wide range of amines. He adds that the method is very simple and practical to carry out. His team has successfully used the reaction to synthesize over 100 different amines, including drug compounds, in fewer steps than would be used in traditional methods. Indeed, some of the amines produced contained sensitive functional groups that couldn’t survive conventional amine synthesis reactions. Baran says, “Our lab has always been driven by pragmatic considerations and cost. We feel that if you’re going to invent a reaction it should probably be accessible to as many people as possible and not be over-engineered,” says Baran. “As for how our technique will fare in the future, time will be the ultimate judge of any synthetic method so let’s check back in five years. At the moment though, we are working on improvements such as rendering alkyl amines in higher yields.”

Newsletters

Receive the latest analytical science news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

References

  1. Jinghan Gui et al., “Practical Olefin Hydroamination with Nitroarenes,” Science 348 (6237), 886-891 (2015).

False

Advertisement

Recommended

False

Related Content

The Final Frontier?
Small Molecules
The Final Frontier?

December 1, 2014

0 min read

The Galactic Grant Competition encourages companies to use the International Space Station for pharmaceutical R&D

Calculate – Don’t Estimate – Drug Development Costs
Small Molecules
Calculate – Don’t Estimate – Drug Development Costs

December 1, 2014

0 min read

Researchers estimate the cost of drug development at over $1 billion, while others say it’s less than $100 million. Who’s right? And how can we accurately determine the true costs?

Electrifying R&D Acceleration
Small Molecules Analytical Science
Electrifying R&D Acceleration

December 2, 2014

0 min read

Electrochemical reaction cells are finding new applications in the pharma R&D lab that could offer big time and cost savings...

United Science Stands
Small Molecules Standards & Regulation
United Science Stands

December 2, 2014

0 min read

Sitting Down With… William Chin, Executive Vice President, Scientific and Regulatory Affairs, Pharmaceutical Research and Manufacturers of America (PhRMA).

The Medicine Maker
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.